Our Clinical Trials
Depression is a major health challenge affecting more than 300 million people globally. Research suggests that 1 in 6 people will experience depression in their lifetime with an 18% increase over the past decade. Of the more than 17 million individuals diagnosed with depression living in the United States, more than 5 million experience treatment-resistant depression. Many of our trials focus on those individuals struggling with treatment-resistant depression.
A Phase III, Multicenter, Randomised, Double-Blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Initial Administrations of COMP360 in Participants with Treatment-Resistant Depression (COMP006)
To learn more about this study, visit the clinicaltrials.gov study page.
Dallas 2K
The Dallas 2K study is a long-term study researching the biological mechanisms of depression and antidepressant treatment response. The D2K study comprises 2,000 participants, over 10 years of age, with a lifetime or current diagnosis of a mood disorder.
Researchers will collect socio-demographic and clinical data, cognitive and psychological assessments, fluid-based biomarkers (blood, urine, saliva), neuroimaging, and EEG. With this information, we hope to create a biosignature to ease treatment selection or identify moderators of response or non-response to treatments in patients with depression. No interventions or treatments will be conducted in the course of the project.
To learn more about this study, visit our clinicaltrials.gov study page.
A Randomized, Double-Blind, Multienter, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (MDD3002)
To learn more about this study, visit the clinicaltrials.gov study page.
An Open-Label, Long-Term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants with Major Depressive Disorder (MDD) (MDD3003)
To learn more about this study, visit the clinicaltrials.gov study page.
Studying the Health of Asians to Advance Knowledge, Treatments, and Interventions for Depression (SHAKTI)
We are currently recruiting English-speaking individuals aged 10 years and older who self-identify as Asian and/or Pacific Islander (e.g., East Asian, South Asian, Southeast Asian, Southwest Asian, Central Asian, Oceanian, Polynesian, Micronesian, Melanesian).
Researchers will collect socio-demographic and clinical data, cognitive and psychological assessments, fluid-based biomarkers (blood, urine, saliva, stool), neuroimaging, and EEG. Participants may attend up to 4 clinic visits per year, and some study procedures may be done remotely.
To learn more about this study, visit our clinicaltrials.gov study page.
Elucidating the neurocircuitry of irritability with high-field neuroimaging to identify novel therapeutic targets
To learn more about this study, visit our clinicaltrials.gov study page.
UTSW Depression Cohort: A Longitudinal Study of Depression
The UTSW Depression Cohort is a longitudinal observational study to describe the longitudinal course of illness and real-world treatment outcomes for depressed patients receiving routine care from their providers.
To learn more about this study, visit our clinicaltrials.gov study page.
Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children with Major Depressive Disorder
To learn more about this study, visit our clinicaltrials.gov study page.
Notable Research
- STAR*D: The first study examining the effectiveness of treatments for treatment-resistant depression
- CO-MED: The first study examining the combination of medication and monotherapy
- TrEAD, DOSE, STRIDE: Major exercise studies in the treatment of mood disorders
- TORDIA and TADS: Pivotal studies in adolescent depression
- EMBARC: First large-scale biomarker evaluation study